33 results
The proposed study is designed to test the hypothesis that the combination of anticoagulants, in particular Dalteparin plus Sunitinib, can be safely administered in a phase I feasibility trial in patients with renal cell cancer in which Sunitinib…
Primary objective:the effects of sedation with clonidine or dexmedetomidine on the duration of haloperidol-resistent delirium in intensive care patientsSecondary objectives:the effect of treatment with clonidine or dexmedetomidine on1. total of…
Primairy objective:To investigate whether the pharmacokinetics of sunitinib are influenced by circadian rhythm.Secondary objective:- to investigate whether daily variation in CYP3A4 activity exists in humans, based on midazolam and 4beta-…
The primary goal of this research is to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for sunitinib and pazopanib in patients with metastatic renal cell carcinoma, so that the possible use of biomarkers can be tested as predictors for the…
The purpose of this study is to observe the usability of Dexmedetomidine and to determine the overall satisfaction of the patient.
To determine whether sunitinib rechallenge in patients with mRCC, who had benefit from prior treatment with sunitinib and who progressed on both sunitinib and second-line therapy (or a period of more than 3 months without treatment), can again…
The main objective of this pilot study is to determine the biological impact of treatment with targeted agents at the systemic and local tissue level in relation to toxicity.
The aim of this study is to determine the patients* and endoscopists experiences and patients* safety with different sedation protocols.
The main objective of this pilot study is to determine intratumoral concentrations of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…
To investigate if sunitinib has clinical significant activity in patients with metastatic/recurrent paraganglioma/pheochromocytoma.
To determine the relation between tumor tissue phosphoproteomic profiles and progression-free survival (PFS) in patients with advanced RCC
To evaluate the probability that the progression free survival (PFS) in the first-line treatment with RAD001 is non-inferior to the first-line treatment with sunitinib for patients with metastatic renal cell carcinoma (primary objective).…
Primary: • To determine the safety and feasibility of PK guided dosing of sunitinib Secondary:• To determine the objective response rate (according RECIST 1.1)• To determine the time to tumor progression and progression free survival• To validate…
To select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.
To assess the therapeutic activity of SU11248 in patients with exptensive disease small cell lung cancer who are either chemonaive or have a sensitive relapse
The purpose of this pilot study is to evaluate the feasibility, efficacy, safety of and patients* compliance to an OA-CPAP for planning a main randomised controlled study. The main objective is to investigate if a patient is treated effective,…
The purpose of this clinical trial is to test whether treatment of patients with NSCLC with erlotinib plus sunitinib is better than treatment with erlotinib plus placebo. All patients enrolling in this study will receive treatment with erlotinib.
To identify predictive factors for response to sunintib treatment in patients with HCC. By discovering changes in pathways involved in HCC carcinogenesis due to sunitinib treatment in tissue/biomarkers and to correlate these changes to FDG-PET scan…
Primary: To observe the correlation between ABCB1 polymorphisms in Exons 13, 22 and 27 and the clearance of sunitinib at steady state. Secondary: - To determine whether ABCB1 genotype correlates with toxicity-adjusted dose of sunitinib - To…